IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Last-Resort access: new drug option for kidney disease patients
Disease control AVAILABLEThis program provides early access to the drug EXV811 (atrasentan) for people with IgA nephropathy, a serious kidney disease, who have no other treatment options. It is for patients who cannot join a clinical trial and whose doctor requests the drug. The goal is to offer potentia…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:23 UTC
-
New drug BHV-1400 tested for kidney disease safety
Disease control Recruiting nowThis early-stage study tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 adults with confirmed IgA nephropathy will receive the drug and be monitored for side effects. The goal is to see if the drug is safe enough to study fu…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated May 26, 2026 05:20 UTC
-
New drug combo aims to slow kidney disease in IgA patients
Disease control Recruiting nowThis study tests whether combining budesonide and ambrisentan can reduce protein in the urine and slow kidney function decline in people with IgA nephropathy, a chronic kidney disease. About 129 adults with mild to moderate kidney damage will receive both drugs for 36 weeks. The …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 26, 2026 05:15 UTC
-
Can a longer course of TARPEYO protect kidneys in IgA disease?
Disease control Recruiting nowThis study looks at whether taking TARPEYO (budesonide) for more than 9 months can further help adults with IgA nephropathy, a kidney disease. About 60 people who have already completed 9 months of TARPEYO will take it for another 19 months. Researchers will check urine and blood…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated May 26, 2026 05:14 UTC
-
Can a simple blood or urine test predict kidney failure years in advance?
Knowledge-focused Recruiting nowThis study follows 2000 people with IgA nephropathy who still have fairly good kidney function. Researchers will check blood and urine samples for markers that might predict if and when kidney disease gets worse. The goal is to find better ways to identify who is at risk, not to …
Matched conditions: IGA NEPHROPATHY
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC